← Back to Search

EHR Tools to Reduce Unsafe Prescriptions for Aging Adults (NUDGE-EHR Trial)

N/A
Waitlist Available
Led By Niteesh K Choudhry, MD, PhD
Research Sponsored by Brigham and Women's Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months
Awards & highlights

NUDGE-EHR Trial Summary

This trial found that using EHR tools, informed by behavioral economics, can help reduce prescribing of unsafe medications for older adults.

Who is the study for?
This trial is for primary care providers at Mass General Brigham, focusing on their patients aged 65 or older who have been prescribed a high volume of benzodiazepines or sedative hypnotics recently. The goal is to improve prescription practices and reduce drug-related side effects in these older adults.Check my eligibility
What is being tested?
The study tests decision support tools embedded in EHR systems designed to help doctors prescribe safer medication alternatives for older adults. It uses behavioral economics principles with interventions like follow-up alerts and pre-commitment strategies to enhance alert effectiveness.See study design
What are the potential side effects?
While the trial itself doesn't involve medications that cause direct side effects, it aims to reduce adverse reactions from unsafe prescriptions such as confusion, excessive sleepiness, hospitalizations, falls, and fractures among elderly patients.

NUDGE-EHR Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Reduction in inappropriate prescribing
Secondary outcome measures
Quantity of high-risk medication prescribed
Other outcome measures
Occurrence of clinically-significant adverse drug events
Pharmaceutical Preparations

NUDGE-EHR Trial Design

3Treatment groups
Experimental Treatment
Active Control
Group I: Open Encounter + Pre-commitmentExperimental Treatment2 Interventions
There will be an enhanced EHR alert, known as a Best Practice Advisory [BPA], which will appear on each provider's EHR screen. We will also test a two-staged pre-commitment BPA in which the providers are prompted to discuss risks of the high-risk medications and share a handout about risks with their patients.
Group II: Open Encounter + Follow-up boosterExperimental Treatment2 Interventions
There will be an enhanced EHR alert, known as a Best Practice Advisory [BPA], which will appear on each provider's EHR screen. We will add a boostering option in the enhanced BPA, which is a provider-directed option for a follow-up in-basket message sent 4 weeks after the BPA is triggered.
Group III: No Alert (Usual Care)Active Control1 Intervention
Providers randomized to usual care will receive no intervention.

Find a Location

Who is running the clinical trial?

Brigham and Women's HospitalLead Sponsor
1,624 Previous Clinical Trials
11,468,223 Total Patients Enrolled
Massachusetts General HospitalOTHER
2,946 Previous Clinical Trials
13,204,423 Total Patients Enrolled
National Institutes of Health (NIH)NIH
2,720 Previous Clinical Trials
7,494,245 Total Patients Enrolled

Media Library

Enhanced Alert Clinical Trial Eligibility Overview. Trial Name: NCT05538065 — N/A
Adverse Drug Reactions Research Study Groups: Open Encounter + Follow-up booster, Open Encounter + Pre-commitment, No Alert (Usual Care)
Adverse Drug Reactions Clinical Trial 2023: Enhanced Alert Highlights & Side Effects. Trial Name: NCT05538065 — N/A
Enhanced Alert 2023 Treatment Timeline for Medical Study. Trial Name: NCT05538065 — N/A
~78 spots leftby Jun 2025